page 1191 indicate that E-cadherin uses an adhesion-independent mechanism to inhibit the invasiveness of human cancer cells.
The authors studied the effects of various E-cadherin constructs on two invasive cell lines derived from breast and prostate cancers. They found that intracellular signaling, not adhesion, mediated E-cadherin's tumor suppressor function. The adhesive portion of E-cadherin, its extracellular domain, was neither necessary nor sufficient to stop invasive behavior. In contrast, constructs containing E-cadherin's cytoplasmic tail, in particular the β-catenin–interacting domain, inhibited the invasive phenotype of the cells.
β-Catenin, as part of the Wnt signaling pathway, activates transcription of a set of target genes that induce cell motility, including a matrix metalloproteinase. E-cadherin can suppress β-catenin action by sequestering the protein from its target genes, and indeed the authors found that loss of β-catenin also stopped invasion. However, invasion inhibition did not depend on transcription of known targets of TCF transcription factors, which are known to associate with β-catenin. This conundrum leaves the authors in search of another β-catenin target, perhaps another transcription factor, that regulates invasiveness. ▪